A Phase 4 interventional study of No endocrine therapy and Endocrine therapy in Breast Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 8 sites in Canada. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one has the largest planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2021, is one of 20 in phase 4, and was the 37th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18–90 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 121 across the 40 interventional studies, 171 across the 4 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
1 of the studies in Breast Neoplasms by Ottawa Hospital Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252726Ottawa Hospital Research InstituteEvaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The current standard of care for stage 1 hormone receptor-positive (HR+) breast cancer consists of breast-conserving surgery followed by adjuvant radiotherapy (RT) and endocrine therapy (ET) for at least 5 years. The benefit of adjuvant ET for older patients is mitigated because of their increase risk of death from other causes and shorter time horizon to live. Clinical and pathological factors such as low-intermediate grade, tumor size ≤2 cm, and older age have been used in a few studies to identify patients with a lower risk of recurrence that might benefit from adjuvant therapy de-escalation, i.e. omission of RT or ET. Since there is no dedicated randomized clinical trial (RCT) conducted to evaluate the omission of ET, there is clinical equipoise as to whether we can omit adjuvant ET in older patients with lower-risk early-stage breast cancer. Therefore, we propose a randomised, multicentre trial evaluating harms and benefits of endocrine therapy in patients ≥70 years of age with lower risk breast cancer.
The current standard of care for stage 1 hormone receptor-positive (HR+) breast cancer consists of breast-conserving surgery followed by adjuvant radiotherapy (RT) and endocrine therapy (ET) for at least 5 years. The benefit of adjuvant ET for older patients is mitigated because of their increase risk of death from other causes and shorter time horizon to live. This population is also more likely to have additional comorbidities which can lead to higher treatment-related adverse events impacting quality of life and precipitating functional decline. Clinical and pathological factors such as low-intermediate grade, tumor size ≤2 cm, and older age have been used in a few studies to identify patients with a lower risk of recurrence that might benefit from adjuvant therapy de-escalation, i.e. omission of RT or ET. The body of evidence from small prospective studies, mathematical modelling study and retrospective analyses would suggest that the omission of ET in older patients with favourable HR+ breast cancer who had optimal local therapy (i.e. breast conserving surgery followed by adjuvant radiotherapy) does not compromise locoregional and survival outcomes. Since there is no dedicated randomized clinical trial (RCT) conducted to evaluate the omission of ET, there is clinical equipoise as to whether we can omit adjuvant ET in older patients with lower-risk early-stage breast cancer. Therefore, we propose a randomised, multicentre trial evaluating harms and benefits of endocrine therapy in patients ≥70 years of age with lower risk breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omission of endocrine therapy
Other: No endocrine therapy
Administration of endocrine therapy for at least 5 years
Other: Endocrine therapy
No endocrine therapy given
Endocrine therapy given for at least 5 years
Hierarchical composite endpoint (OS, iDFS, MDFS, QoL)
The primary outcome is a hierarchical composite endpoint following the WIN-ratio approach. This composite endpoint includes overall survival (OS), invasive disease free survival (iDFS), metastatic disease free survival (MDFS), quality of life (QoL), joint pain, and hot flashes.
Time frame: 5 years
Overall survival
Overall survival (OS) is the time from the date of surgery to the date of death due to any cause.
Time frame: 5 years
Invasive disease free survival
Invasive disease free suvival (iDFS) is the time from the surgery until the first occurrence of invasive ipsilateral, loco-regional, contralateral and distant breast tumor recurrence or death due to any cause
Time frame: 5 years
Metastatic disease free survival
Metastatic disease free survival (MDFS) is the time from the surgery until the first occurrence of distant breast tumor recurrence of death due to any causes
Time frame: 5 years
Health-related quality of life: FACT-B plus ES
Health-related quality of life is measured using the Functional Assessment of Cancer Therapy - Breast (FACT-B) plus the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES). The FACT-B has a total score of 0 to 148. FACT-ES has a total score of 0 to 184. Higher scores indicate better quality of life.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Hot flashes
Hot flashes measured using the validated FACT-B plus ES (questions ES1-3). Worsening of hot flashes will be defined as an increase by 1 of the hot flashes score compared to baseline. Improvement will be defined as a decrease of 1 of the hot flashes score compared to baseline.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Joint pain
Joint pain measured using the validated FACT-B plus ES (question BRM1). Worsening of join pain will be defined as an increase by 1 of the joint pain score compared to baseline. Improvement of join pain will be defined as a decrease of 1 of the the join pain score compared to baseline.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Health-related quality of life: FACT-G
Health-related quality of life will be measured with the Functional Assessment of Cancer Therapy - General (FACT-G) 27-item questionnaire. FACT-G scores range from 0 to 108. Higher scores indicate better quality of life.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Health-related quality of life: EQ-5D-5L
The EQ-5D-5L questionnaire includes 6 self-reported quality of life items.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Breast Cancer Specific Survival
Breast Cancer Specific Survival (BCSS) is the time from the date of surgery to the date of death from the breast cancer.
Time frame: 5 years
Adverse events of interest
The number of participants with each adverse events of interest: bone fracture, cerebrovascular event, thromboembolic event, cardiovascular event, secondary cancer, hospitalization and death.
Time frame: 5 years
Change in geriatric domains
Change in geriatric domains (e.g. functional status, comorbidities, medications, nutritional status, cognitive function, and psychosocial status) using CARG score patient tool.
Time frame: Baseline, 1 year, 5 years
Adherence with prescribed endocrine therapy
Adherence with prescribed endocrine therapy will be measured by the validated Five-Item Medication Adherence Report Scale (MARS-5 score) in Arm B only.
Time frame: 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Quality-adjusted life years (QALY)
QALYs are estimated by multiplying the time spent in each health state by the corresponding utility value and summing these values across all model cycles over the time horizon.
Time frame: 5 years
Beliefs about Medicine Questionnaire - adjuvant endocrine therapy (BMQ-AET)
Participants in arm B will complete the Beliefs about Medicine Questionnaire - adjuvant endocrine therapy (BMQ-AET). This includes 10 self-reported items.
Time frame: Baseline, 26-weeks, 1-year, 2-years, 3-years, 4-years, 5-years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Aug 2021 (actual). Primary completion is estimated for May 2036, 177 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 177 months is above that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute →